The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education

Butorov V.N.

Russian Medical Academy for Continuous Professional Education

Kochetkov A.I.

Russian Medical Academy of Continuous Professional Education

Klepikova M.V.

Russian Medical Academy for Continuous Professional Education

Golovina O.V.

Russian Medical Academy for Continuous Professional Education

Telmisartan combined with moxonidine in the treatment of arterial hypertension in obese patients

Authors:

Ostroumova O.D., Butorov V.N., Kochetkov A.I., Klepikova M.V., Golovina O.V.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5): 452‑458

DOI: 10.17116/kardio202013051452

Read: 24480 times

Download PDF (RU)
Contact the author
Table of contents

TELMISARTAN COMBINED WITH MOXONIDINE IN THE TREATMENT OF ARTERIAL HYPERTENSION IN OBESE PATIENTS
TELMISARTAN COMBINED WITH MOXONIDINE IN THE TREATMENT OF ARTERIAL HYPERTENSION IN OBESE PATIENTS

To cite this article:

Ostroumova OD, Butorov VN, Kochetkov AI, Klepikova MV, Golovina OV. Telmisartan combined with moxonidine in the treatment of arterial hypertension in obese patients. Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5):452‑458. (In Russ.)
https://doi.org/10.17116/kardio202013051452

ЭндоКард
Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):125-129
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
Reso­lution of the expert council «Possibilities of neuroprotective therapy in patients with arte­rial hype­rtension and cognitive diso­rders». Russian Journal of Preventive Medi­cine. 2024;(11):85-93
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Modern view on the etiology of gallstone disease in children. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):59-68
Options for the surgical technique of lapa­roscopic sleeve gastrectomy for prevention and treatment of gastroesophageal reflux in patients with obesity. Endo­scopic Surgery. 2024;(6):57-68
Predictors of Enga­gement and Active participation of Patients with Unco­ntrolled Hype­rtension in the Tele­health Surveillance Program. Russian Journal of Preventive Medi­cine. 2024;(12):37-43
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Cuffless methods of blood pressure measurements. Review of modern technologies. Russian Journal of Preventive Medi­cine. 2024;(12):156-162
Deve­lopment of a method for moxo­nidine quantification in blood and urine by high-performance liquid chro­matography with tandem mass-selective dete­ction. Fore­nsic Medi­cal Expe­rtise. 2024;(6):42-47
Abstract:

Overweight or obese are observed in 60% of patients with arterial hypertension (AH) that increases cardiovascular risk. According to the current guidelines, these patients are needed to prescribe a combination of two antihypertensive drugs as a starting therapy. In this clinical case, telmisartan with moxonidine were used in a patient with hypertension, obesity, dyslipidemia and impaired glucose tolerance. High antihypertensive effectiveness of this combination was confirmed by 24-houir blood pressure monitoring. Literature data on the beneficial effect of telmisartan on the risk of cardiovascular complications are presented. Unlike other angiotensin II receptor blockers, telmisartan activates PPAR-γ receptors that improves glucose and lipid metabolism. Moxonidine increases tissue sensitivity to insulin in patients with overweight, insulin resistance and impaired glucose metabolism. Co-administration of moxonidine and telmisartan is one of the possible strategies for antihypertensive therapy in patients with hypertension and obesity.

Keywords:

arterial hypertension
obesity
antihypertensive therapy
telmisartan
moxonidine

Authors:

Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education

Butorov V.N.

Russian Medical Academy for Continuous Professional Education

Kochetkov A.I.

Russian Medical Academy of Continuous Professional Education

Klepikova M.V.

Russian Medical Academy for Continuous Professional Education

Golovina O.V.

Russian Medical Academy for Continuous Professional Education

Received:

30.07.2020

Accepted:

19.08.2020

Close metadata

References:

  1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi, M., Burnier, M. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  2. Shalnova SA, Deev AD, Balanova YuA, Kapustina AV, Konstantinov VV, Muromtseva GA, Boytsov SA. Dynamics of arterial hypertension in Russia: is there any progress in prescribing antihypertensive therapy? (results from 1993-2013). Serdtse: zhurnal dlya praktikuyushchikh vrachej. 2015;14(6):389-396. (In Russ.).
  3. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8(1):9418. https://doi.org/10.1038/s41598-018-27377-2
  4. Shalnova SA, Deev AD, Balanova YuA, Kapustina AV, Imaeva AE, Muromtseva GA, Kiselyova NV, Boytsov SA. Twenty-year trends of obesity and arterial hypertension and their association in Russia. Kardiovaskulyarnaya terapiya i profilaktika. 2017;16(4):4-10. (In Russ.). https://doi.org/10.15829/1728-8800-2017-4-4-10
  5. Balanova YuA, Shalnova SA, Deev AD, Imaeva AE, Kontsevaya AV, Muromtseva GA, Kapustina AV, Evstifeeva SE, Drapkina OV. Obesity in the Russian population — a prevalence and association with risk factors for chronic nonconcomunicable diseases. Rossijskij kardiologicheskij zhurnal. 2018;23(6):123-130. (In Russ.). https://doi.org/10.15829/1560-4071-2018-6-123-130
  6. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015; 16(1):1-12.  https://doi.org/10.1111/obr.12229
  7. Aronow WS. Association of obesity with hypertension. Ann Transl Med. 2017;5(17):350.  https://doi.org/10.21037/atm.2017.06.69
  8. https://doi.org/10.15829/1560-4071-2020-3-3786  https://doi.org/10.15829/1560-4071-2020-3-3786
  9. Chazova IE, Mychka VB. New opportunities in the treatment of patients with metabolic syndrome: results of the ALMAZ study. Sistemnye gipertenzii. 2006;3(2):14-17. (In Russ.). https://syst-hypertension.ru/2075-082X/article/view/28759
  10. Simonenko VB, Goryutsky VN, Dulin PA. Role of insulinorestentity in pathogenesis of arterial hypertension. Klinicheskaya meditsina. 2014;92(9):27-33. (In Russ.).
  11. Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Di Mario U. The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity. European Journal of Human Genetics. 2004;12(12):1050-1054. https://doi.org/10.1038/sj.ejhg.5201283
  12. Barbarash OL, Zvereva TN. The combination of sartan and calcium antagonist is new horizons in the treatment of hypertension. Consilium Medicum. 2014;16(05):5-10. (In Russ.)..
  13. Derosa G, Cicero AFG, D’Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SAT, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy I type 2 diabetic patients treated with rosiglitazone: effects on insulin resistance, laptin and tumor necrosis factor-α. Hypertens Res. 2006;29(11): 849-856.  https://doi.org/10.1291/hypres.29.849
  14. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27(7):457-464.  https://doi.org/10.1291/hypres.27.457
  15. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25(1):41-46.  https://doi.org/10.1038/sj.bjp.0707323
  16. Williams B, Gosse P, Lowe L, Harper R. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24(1):193-200.  https://doi.org/10.1097/01.hjh.0000194364.11516.ab
  17. Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res. 2005;33(Suppl 1):39-49.  https://doi.org/10.1177/14732300050330S106
  18. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A., Murohashi-Bokuda K, Itoh H. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res. 2010;33(4):304-312.  https://doi.org/10.1159/000316724
  19. Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364-369.  https://doi.org/10.1038/ki.2008.204
  20. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177-185.  https://doi.org/10.1038/sj.jhh.1001964
  21. The ONTARGET Investigators: Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM. 2008;358(15):1547-1559. https://doi.org/10.1056/NEJMoa0801317
  22. Sanjuliani AF, Deabreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60(5):621-629.  https://doi.org/10.1111/j.1368-5031.2006.00951.x
  23. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18(9):669-675.  https://doi.org/10.1038/sj.jhh.1001676
  24. Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. International Journal of Hypertension. 2013;2013:1-9.  https://doi.org/10.1155/2013/541689
  25. Littlewood KJ, Greiner W, Baum D, Zoellner Y. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrol. 2007;8(1):1-8.  https://doi.org/10.1186/1471-2369-8-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.